1 Title: HLA-A*02:01 allele is associated with decreased risk and a longer survival in

2 pancreatic cancer: Results from an exhaustive analysis of the *HLA* variation in PDAC

3

Alberto Langtry¹, Raul Rabadan², Lola Alonso¹, Casper van Eijck^{1,3}, Authors: 4 Teresa Macarulla⁴, Rita T Lawlor⁵, Alfredo Carrato⁶, Rafael Alvarez-Gallego⁷, Mar 5 Iglesias⁸, Xavier Molero⁹, J Matthias Löhr¹⁰, Christopher W Michalski¹¹, José Perea¹², 6 Michael O'Rorke¹³, Víctor M Barberà¹⁴, Adonina Tardón¹⁵, Antoni Farré¹⁶, Luís 7 Muñoz-Bellvís¹⁷, Tatjana Crnogorac-Jurcevic¹⁸, Enrique Domínguez-Muñoz¹⁹, 8 Thomas Gress²⁰, William Greenhalf²¹, Linda Sharp²², Sergio Sabroso-Lasa¹, Ioan 9 Filip², Gaby Strijk³, Florian Castet⁴, Joaquim Balsells⁹, Eithne Costello²¹, Jörg 10 Kleeff²³, Bo Kong²⁴, Josefina Mora¹⁶, Damian O'Driscoll²⁵, Aldo Scarpa⁵, Weimin 11 Ye²⁶, Francisco X. Real²⁷, Núria Malats^{1*}, Evangelina López de Maturana^{1*}, on behalf 12 of the PanGenEU Investigators²⁸ 13

14

15 Authors' affiliations:

- (1) Genetic and Molecular Epidemiology Group, Spanish National Cancer
 Research Center (CNIO), and CIBERONC, Madrid, Spain.
- 18 (2) Department of Systems Biology, Columbia University, New York, NY, USA.
- 19 (3) Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
- 20 (4) Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall
 21 d'Hebron, Barcelona, Barcelona, Spain.
- (5) ARC-Net Center for Applied Research on Cancer, Department of Diagnostics
 and Public Health and Department of Engineering for Innovation Medicine ,
 University of Verona, Verona, Italy.
- (6) Department of Oncology, Ramón y Cajal University Hospital, IRYCIS, Alcala
 University, Madrid, and CIBERONC, Spain.
- (7) HM CIOCC Madrid (Centro Integral Oncológico Clara Campal). Hospital
 Universitario HM Sanchinarro. Instituto de Investigación Sanitaria HM
 Hospitales. Facultad HM de Ciencias de la Salud de la Universidad Camilo
 José Cela.
- 31 (8) Hospital del Mar—Parc de Salut Mar, Barcelona, and CIBERONC, Spain.
- 32 (9) Hospitals Universitaris Arnau de Vilanova i Santa Maria, IRBLleida, UdL,
 33 25198, Lleida; and CIBEREHD, Madrid, Spain.

34	(10)	Gastrocentrum, Karolinska Institutet and University Hospital,					
35	Stock	kholm, Sweden.					
36	(11)	Department of Surgery, Technical University of Munich, Munich; and					
37	Department of General, Visceral and Transplantation Surgery, Medical Faculty						
38	Heid	elberg, University Heidelberg, Germany.					
39	(12)	Department of Surgery, Hospital 12 de Octubre, Madrid; and Institute					
40	of Bi	of Biomedical Research of Salamanca, Salamanca, Spain.					
41	(13)	Center for Public Health, Belfast, Queen's University Belfast, UK; and					
42	Colle	ege of Public Health, The University of Iowa, Iowa City, IA, US.					
43	(14)	Molecular Genetics Laboratory, General University Hospital of Elche,					
44	Spair	n.					
45	(15)	Department of Medicine, Instituto Universitario de Oncología del					
46	Princ	cipado de Asturias (IUOPA), Instituto de Investigación Sanitaria del					
47	Princ	cipado de Asturias (ISPA), Oviedo, and CIBERESP, Spain.					
48	(16)	Department of Gastroenterology and Clinical Biochemistry, Hospital de					
49	la Sa	nta Creu i Sant Pau, Barcelona, Spain.					
50	(17)	Department of Surgery, Hospital Universitario de Salamanca – IBSAL.					
51	Univ	Universidad de Salamanca and CIBERONC, Spain.					
52	(18)	Barts Cancer Institute, Center for Cancer Biomarkers and					
53	Bioth	nerapeutics, Queen Mary University of London, London, UK.					
54	(19)	Department of Gastroenterology, University Clinical Hospital of					
55	Santi	iago de Compostela, Spain.					
56	(20)	Department of Gastroenterology, University Hospital of Giessen and					
57	Marb	burg, Marburg, Germany.					
58	(21)	Department of Molecular and Clinical Cancer Medicine, University of					
59	Liver	rpool, Liverpool, UK.					
60	(22)	National Cancer Registry Ireland and HRB Clinical Research Facility,					
61	University College Cork, Cork, Ireland; and Newcastle University, Institute of						
62	Healt	th & Society, Newcastle, UK.					
63	(23)	Department of Surgery, Technical University of Munich, Munich; and					
64	Depa	artment of Visceral, Vascular and Endocrine Surgery, Martin-Luther-					
65	Univ	ersity Wittenberg-Halle (Saale), Germany.					
66	(24)	Department of Surgery, Technical University of Munich, Munich					

67	(25) National Cancer Registry Ireland and HRB Clinical Research Facility,
68	University College Cork, Cork, Ireland.
69	(26) Department of Medical Epidemiology and Biostatistics, Karolinska
70	Institutet, Stockholm, Sweden.
71	(27) Epithelial Carcinogenesis Group, Spanish National Cancer Research
72	Center (CNIO) and CIBERONC, Madrid; and Pompeu Fabra University,
73	Barcelona, Spain.
74	(28) In Annex 1.
75	
76	*Co-senior authors
77	
78	Correspondence to: Núria Malats, and Evangelina López de Maturana Genetic and
79	Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO),
80	C/Melchor Fernández Almagro 3, 28029-Madrid, Spain, Email: nmalats@cnio.es, and
81	melopezdm@cnio.es. Phone: +34 917328000
82	
83	ABSTRACT
84	Genetic susceptibility loci are associated with PDAC risk and survival, but the impact

85 of germline HLA region variation remains largely unexplored. This study examined HLA I-II alleles within the PanGenEU study and validated our findings using external 86 87 datasets (UK Biobank, TCGA, PAN-NGS trial, and Caris trial). HLA-A*02:01and HLA-B*49 alleles were linked to a decreased risk of PDAC, whereas HLA-B*39, 88 89 HLA-DPB1*04, and HLA-A*26:01 were directly associated with increased risk. 90 PDAC patients carrying the HLA-A*02:01 allele also showed lower mortality rates, with the effect being more pronounced in those with $KRAS^{G12V}$ mutations, pointing to 91 92 a host*tumor genetic interaction. This research highlights HLA-A*02:01, found in 20% of Europeans, as a marker for reduced PDAC risk and mortality, especially in 93 KRAS^{G12V} mutated tumors. Results from this study could enhance personalized 94 95 medicine for PDAC by identifying patients who may benefit from regular screenings

- 96 through tailored risk assessments. Importantly, our findings are crucial for stratifying
- 97 PDAC patients based on their genetic background and tumor mutational profile, which
- 98 can guide treatment strategies.
- 99

100 INTRODUCTION

101 Pancreatic cancer has a dismal prognosis with a 5-year survival rate of 5-10% (1–3) 102 and a 10-year survival rate of 1% (4). Worryingly, it is expected to become the second 103 cause of cancer-related deaths in the USA by 2030 if action is not taken (5). Pancreatic 104 ductal adenocarcinoma (PDAC) is the most common form of these neoplasms. So far, 105 great efforts are being made to advance its diagnosis and detect tumors at early stages 106 to improve survival (6–8). Identifying the genetic and non-genetic factors involved in 107 PDAC etiology is crucial for defining high-risk individuals who would benefit from 108 detecting the tumor when it is still curable. However, there is no definition of high-109 risk individuals for sporadic PDAC, those representing 90% of the burden of the 110 disease.

111 We previously reported an inverse association between PDAC risk and nasal 112 allergies, asthma, and autoimmune diseases (9,10), conditions characterized by an 113 overactive immune response. Furthermore, our recent multilayered GWAS approach 114 (11) identified a hotspot in the Major Histocompatibility Complex (MHC) region, where the alternative allele of the top targeted Human Leukocyte Antigen (HLA) G115 gene was associated with increased PDAC risk (p-value= 1.8×10^{-4}). In addition, several 116 117 GWAS hits at this region have been associated with the risk of other cancer types like 118 breast (12) or lung cancer (13,14), as well as with well-established PDAC risk and 119 protective factors such as chronic immune-related diseases (15,16), diabetes (17,18), 120 smoking (19), asthma (20,21), and nasal allergies (22). The lack of GWAS-reported 121 PDAC genetic susceptibility loci in the *MHC* region might be because SNPs are not 122 fully capturing the variability of the *MHC*. On the other hand, at the tumor level, Filip 123 et al. (2023) (23) reported that Allele-Specific Expression loss of the HLA class I 124 genes in PDAC, among other cancers, is associated with a worse prognosis.

125	The MHC is essential for the proper response of the immune system against
126	tumor cells (24). The MHC genetic complex is a dense cluster of genes located at the
127	6p21.1-21.3 chromosome cytoband (28,477,797-33,448,354 bp, GRCh37), and it
128	includes three HLA sub-regions. HLA class I can be classified into classical (HLA-A, -
129	B, and -C) and non-classical genes (HLA-E, -F, and -G). HLA class II genes are HLA-
130	DR, -DQ, and -DP. HLA class I and II proteins present intracellular and extracellular
131	peptides to $CD8^+$ and $CD4^+$ T-cells, respectively (25,26). The <i>MHC</i> region also shows
132	an extensive linkage disequilibrium (27). As a consequence of its complexity, the role
133	of this region has not yet been studied in-depth in relation to the risk of cancer and,
134	more specifically, PDAC.

135 Here, we report an exhaustive study on PDAC genetic susceptibility associated 136 with the *MHC* region variation on *HLA* class I and II alleles, haplotypes, and amino 137 acids (Fig. 1). We performed association analyses at the HLA allele and haplotype 138 levels in PanGenEU, one of the largest PDAC case-control studies with extensive 139 standardized clinical and epidemiological data annotation. We then tested these associations in an independent population, the UK Biobank (UKB), and computed 140 global risk estimates by meta-analyzing the results from the two consortia. We also 141 142 deliver for the first time an estimate of the heritability for PDAC risk explained by the 143 HLA class I and II variation. Furthermore, we used the resources from TCGA, UKB, 144 and PanGenEU to conduct a meta-analysis on the HLA alleles' overall survival (OS) 145 associations. Finally, we assessed the association between the most promising alleles 146 and common KRAS mutations using TCGA data and validated results with PAN-NGS 147 and Caris trials. Altogether, our findings underscore the role of the HLA region in 148 PDAC genetic susceptibility and prognosis. Our findings may have implications for 149 the design of mutant KRAS-based vaccines in PDAC.

150 **RESULTS**

151 *Characteristics of the study populations*

152 The characteristics of the PanGenEU, UK Biobank, and TCGA study populations are 153 available in **Supplementary Table S1**. PanGenEU participants were Caucasian from Spain (58.8%), Italy (22.6%), Sweden (7.9%), Germany (6.7%), UK (3.7%), and 154 155 Ireland (0.2%). The average age was similar between cases and controls in each study population; however, UKB controls were, on average, younger than cases. A slightly 156 157 lower proportion of females across the studies was observed for both cases and controls. In the PanGenEU and UKB populations, cases were more frequently 158 159 smokers and diabetic, while controls had a higher prevalence of asthma and allergies. 160 Finally, the median survival was shorter for UKB patients than for TCGA and 161 PanGenEU patients. As expected based on study design, TCGA included a higher 162 proportion of patients with early-stage tumors than PanGenEU cases. We also 163 observed significant differences in the stage of the tumors across populations, being 164 the Caris clinical trial the population with the highest proportion of stage III-IV PDAC tumors. The median survival time of the UKB patients was significantly shorter 165 compared to the PanGenEU, TCGA, Erasmus, and Caris patients. Finally, neoadjuvant 166 167 and adjuvant settings were significantly different between the Erasmus and Caris 168 populations.

169

170 Association analyses between HLA alleles and PDAC risk

HLA class I and class II alleles explain 11% of the PDAC risk. Bayesian multi kernelbased regression allowed us to obtain the genetic and residual variance components $(\sigma_{HLA-I}^2 = 0.013, \sigma_{HLA-II}^2 = 0.010, \text{ and } \sigma_e^2 = 0.174)$ and therefore, the heritability estimates for *HLA* class I and class II alleles were: $h_{HLA-I}^2 = 0.06$ and $h_{HLA-II}^2 = 0.05$.

175 Supplementary Fig. S1A and S1B show the landscape of HLA class I and II 176 alleles at two-field level in PanGenEU and UKB populations, respectively. HLA-B 177 was the most polymorphic MHC gene in both populations: 97/298 (32.6%), two-field 178 HLA alleles in the PanGenEU and 108/306 (35.3%) in UKB. Some alleles, like HLA-179 DPA1*01:03, showed large variability across populations. In general, the AF matched 180 expected European frequencies (28). The AF in PanGenEU showed good correlations with the T1DGC reference panel (R=0.92 and R=0.86, for one- (allele group) and two-181 182 fields (HLA protein) HLA alleles, see, Supplementary Fig. S2A and S2B) and 183 moderate correlation with UKB (R=0.57, see Supplementary Fig. **S3**). 184 Supplementary Table S2 summarizes the number of HLA class I and II alleles 185 considered in the association analyses after filtering out those with poor imputation 186 quality and low AF.

187 In our comprehensive meta-analysis of the PanGenEU and UKB populations, 188 the following four alleles yielded significant associations with PDAC risk: HLA-A*02:01 (OR=0.86, p-value=1.88x10⁻³), *HLA-B*49* (OR=0.68, p-value=3.81x10⁻²), 189 *HLA-B**39 (OR=1.42, p-value= 1.99×10^{-2}), and *HLA-DPB1**04 (OR=1.1, p-190 value= 2.86×10^{-2}) (Fig. 2). After multiple testing correction, only the HLA-A*02:01 191 remained significant (OR=0.86, corrected p-value=2.25x10⁻², Supplementary Table 192 193 **S3**). We also explored the association between the above-mentioned *HLA* alleles and 194 the established PDAC risk factors. Interestingly, we observed a significant inverse 195 association between HLA-B*39 and nasal allergies, which is protective against PDAC $(OR=0.84, p-value=1.15 \times 10^{-4}, see Fig. 2C).$ 196

Furthermore, the PanGenEU study identified one allele significantly associated with PDAC: the *HLA* class I A*26:01 (OR=1.75, corrected p-value=4.17x10⁻²). Individuals carrying this allele, present in 5% of the PanGenEU study population,

200 showed a higher risk of developing PDAC (OR=1.74, Supplementary Table S4). 201 Additionally, when both controls and cases were combined to increase statistical power, we found that this allele was significantly and inversely associated with nasal 202 allergies (OR=0.56, p-value= 2.87×10^{-2}) and, although non-significantly, with asthma 203 $(OR=0.68, p-value=2.2x10^{-1}, Supplementary Fig. S4A)$. However, we did not 204 205 replicate the association between HLA-A*26:01 and PDAC risk in the UKB study 206 (Supplementary Table S5) nor the meta-analysis, although the direction of the association was the same (OR=1.07, p-value=9.88x10⁻¹). 207

208

209 *Cumulative PDAC risk score for the most promising alleles*

210 We estimated cumulative PDAC risk by combining known risk and protective factors 211 and adding PDAC-associated HLA alleles. In a meta-analysis with the UK Biobank, 212 individuals with the abovementioned non-genetic high-risk conditions had 2.8 times 213 higher PDAC risk. By including either HLA-B*39 or HLA-DPB1*04 alleles, the ORs 214 increased to 5.28 and 3.34, respectively (**Table 1**), though not statistically significant $(p-value=1.17x10^{-1}, p-value=1.33x10^{-1}, respectively)$. Conversely, asthmatic or 215 216 allergic individuals who did not smoke, had no diabetes, nor had a family history of 217 PDAC, experienced a 62% reduction in the odds (OR=0.38) of developing PDAC. 218 Subjects who had one/two alleles of HLA-A*02:01 further decreased their ORs to 0.32 and 0.27, respectively (p-value= 1.18×10^{-2}). By including one/two copies of the HLA-219 B*49 allele in the model, the OR significantly decreased to 0.19 and 0.1 (p-220 value= 2.4×10^{-2} , **Table 1**). Additionally, in the PanGenEU study, diabetics, smokers, 221 222 and individuals with a family history of cancer but without asthma or allergies had 223 4.33 times higher risk of PDAC than the population in the lowest risk category. When 224 those individuals at high-risk harbor one or two copies of the HLA-A*26:01 allele, the

ORs increased to 7.73 and 13.81, respectively (p-value=2.28x10⁻², see
Supplementary Fig. S4B).

227

228 Association analyses between HLA haplotypes and PDAC risk

229 Given the critical role of *HLA* haplotypes in immune responses, we assessed their association with PDAC risk. We identified 18 haplotypes significantly associated with 230 231 PDAC risk, nine of which remained significant after multiple testing correction 232 (Supplementary Table S6). Two of the top five protective haplotypes carried the 233 HLA-A*02 allele, present in 20% of the European population and associated with 234 decreased PDAC risk in our analyses. Haplotypes harboring the HLA-A*02 allele were 235 all protective for PDAC, some reaching an $OR \sim 0.4$). Among the haplotypes with the 236 lowest effect size HLA-B*35 and HLA-A*02 alleles were common: HLA-B*35/HLA-237 A*02 (OR=0.41, 95%CI=0.18-0.94), *HLA-DRB1*13/HLA-B*35* (OR=0.43, 238 95%CI=0.38-0.5), and HLA-DRB1*01/HLA-A*02 (OR=0.49, 95%CI=0.27-0.89). On 239 the contrary, the highest risk haplotypes harbored the HLA-DRB1*04 allele: HLA-240 *DRB1*04/HLA-B*44/HLA-C*07* (OR=1.19, 95%CI=1.12-1.26) and HLA-241 *DRB*04/HLA-B*14* (OR=1.28, 95%CI=1.19-1.38) (Supplementary Table S6).

The *HLA-A*26*, *HLA-B*39*, and *HLA-B*49* alleles were not part of the haplotypes significantly associated with PDAC risk in the meta-analysis, probably because of their low AF: *HLA-A*26*=0.02, *HLA-B*39*=0.02, and *HLA-B*49*=0.01.

245

246 HLA alleles are associated with overall survival of PDAC patients

We further assessed the role of *HLA* alleles in PDAC prognosis through a metaanalysis of the results from the survival analyses in PanGenEU, UK Biobank, and TCGA studies. 156 *HLA* class I and II alleles overlapped between the three studies

250 (Supplementary Fig. S5). The results obtained under a dominant MoI revealed that patients who carried the HLA-A*02:01 allele presented better survival than non-251 carriers (HR=0.87, p-value= 3.3×10^{-2} , Fig. 3), indicating that a single copy of this 252 253 allele is enough to improve survival. On the other hand, homozygous individuals for HLA-DPB1*04 displayed a borderline significantly worse survival under a 254 codominance model (HR=1.19, p-value= 6.3×10^{-2} , Supplementary Fig. S6). 255 Additionally, carriers of HLA-A*30:01 (HR=1.75, p-value=1.2x10⁻²), and HLA-256 DPB1*09:01 (HR=3.36, p-value=1.5x10⁻³) were also associated with worse overall 257 258 survival compared to non-carriers (Supplementary Fig. S7).

259

260 HLA-A*02:01 interacts with KRAS^{G12V} mutations for PDAC survival

More than 90% of PDAC harbor *KRAS* mutations. We found that the PDAC protective allele *HLA-A**02:01 was associated with tumors harboring *KRAS*^{G12V} vs. other mutations in PDAC, NSCLC, and colorectal cancers (OR=1.55, pvalue= 4.65×10^{-2}), and with *KRAS*^{G12D} mutations in gastric tumors (OR=7.27, pvalue= 6.42×10^{-3}) (**Supplementary Table S7**).

Stratified analysis revealed that HLA-A*02:01 carriers with KRAS^{G12V} tumors 266 had significantly better survival (HR=0.19, p-value= 1.3×10^{-2} , Fig. 4A) than HLA-267 A*02:01 carriers with other KRAS mutations; importantly, survival did not differ for 268 patients with $KRAS^{G12V}$ mutated tumors who did not carry the HLA-A*02:01 allele 269 270 (HR=0.87, p-value= 8.1×10^{-1} , Fig. 4B). Conversely, carriers of HLA-A*02:01 and *KRAS*^{G12D} had significantly worse survival (HR=5.51, p-value= 1.5×10^{-3} , Fig. 4C) than 271 272 non-carriers (HR=1.13, p-value= 6.2×10^{-1} , Fig. 4D). Further stratified analyses focusing on individuals carrying either the KRAS^{G12V} or KRAS^{G12D} mutations, along 273 274 with the presence or absence of the HLA-A*02:01 allele, showed that the longer

survival of *KRAS*^{G12V} carriers appear to be driven by the interaction with the *HLA*-*A**02:01 allele (HR=0.13, p-value=4.4x10⁻², **Fig. 5A**). However, for those with *KRAS*^{G12D} mutated tumors, the decreased survival was mainly due to the mutation itself, regardless of the *HLA* allele (HR=1.21, p-value=2.2x10⁻¹, **Fig. 5B**). Interestingly, we discovered that *KRAS*^{G12D} mutated tumors, displayed a significant higher expression level of IFN-γ in comparison to tumors carrying any of the other *KRAS* mutations (**Supplementary Fig. S8**).

282 The interaction model in the TCGA study showed that carriers of the HLA-A*02:01 allele who had a KRAS^{G12V} mutated tumor had a significantly lower risk of 283 284 death (HR=0.14, p-value= 2.4×10^{-2}) compared to patients with any of the other KRAS 285 mutations, adjusted for gender, age at diagnosis, stage, and Moffit tumor subtype. We 286 then performed a meta-analysis of the interaction between the A*02:01 allele and *KRAS*^{G12V} mutations, including the PAN-NGS and Caris populations (**Supplementary** 287 288 Fig. S9). This interaction held significant in early-stage tumors (HR=0.25, pvalue= 1.7×10^{-2} , Fig. 6A) but not in advanced-stage (HR=0.93, p-value= 8.7×10^{-1} , Fig. 289 290 **6B**).

291

292 **DISCUSSION**

The present study represents the most exhaustive analysis of the role of the *MHC* region at the *HLA* allele and haplotype levels associated with PDAC risk and prognosis. We show that different *MHC* genetic profiles recognize distinct PDAC risk populations. We identified five novel susceptibility alleles in the *HLA* class I and II regions associated with PDAC risk: *HLA-A**26:01, *HLA-A**02:01, *HLA-B**49, *HLA-B**39, and *HLA-DPB1**04. Among these, *HLA-A**02:01 remained significant after correcting for multiple testing, showing a notably reduced risk of PDAC

300	(metaOR=0.86, corrected p-value= 2.25×10^{-2} . This allele is prevalent in 20% of the
301	European population, and was present in all the protective haplotypes. Interestingly,
302	HLA-A*02:01 has been found to be associated also with a decreased risk of
303	melanoma (29). Importantly, we found that germline HLA-A*02:01 carriers with
304	PDAC from the PanGenEU, UKB, TCGA, and Caris had a survival benefit
305	(metaHR=0.87, p-value= 3.3×10^{-2} ; Fig. 3B). These findings go along with the
306	observations that HLA-A*02:01 carriers have better survival in NSCLC (30), and
307	might have improved outcomes to immunotherapy (31), pointing to HLA-A*02:01 as a
308	good prognostic marker for PDAC. Notably, the HLA-A*02:01 allele is among the
309	eligibility criteria in different cancer immunotherapy clinical trials for esophageal
310	carcinoma (32), acute myeloid leukemia (33), NSCLC (34), and glioblastoma
311	(currently in phase III) (35).

312 Since HLA-A*02:01 has shown a high predicted binding affinity for the KRAS codon 12 mutation in silico-in vitro studies (36), we also assessed the association of 313 HLA-A*02:01 with the most common hotspot KRAS mutations (at codons 12, 13, and 314 61) in KRAS-mutated cancers (PDAC, NSCLC, stomach, and colorectal) using TCGA 315 316 data. After adjusting for cancer type, we discovered that HLA-A*02:01 is preferentially associated with tumors harboring KRAS^{G12V} mutations (OR=1.55, p-317 value= 4.65×10^{-2}). Remarkably, we observed that patients with KRAS^{G12V} mutated 318 tumors who carried the HLA-A*02:01, comprising approximately 5% of the PDAC 319 320 patients, experienced significantly better survival compared to those without the allele. This novel interaction was confirmed in an independent series of resectable (or early-321 322 stage) PDAC cases (PAN-NGS). Supporting this host-tumor interaction, the NEPdb 323 (https://nep.whu.edu.cn/) database, which includes data on over 17K validated human immunogenic neoantigens, shows that only KRAS^{G12V} and KRAS^{G12D} mutations have 324

been validated to bind the *HLA-A*02:01* protein and elicit an immune response. Conversely, regardless of the HLA allele, patients with *KRAS*^{G12D}-mutant tumors had significantly worse survival than those without this mutation. However, the PAN-NGS and Caris independent datasets could not validate this finding.

329 Therefore, this study is a pioneer in showing that the presence of *HLA-A**02:01 330 allele not only is associated with protection against PDAC risk but it is also associated with better PDAC survival, mainly in patients with early-stage KRAS^{G12V} mutant 331 tumours. Our findings could lead to an *HLA-A*02:01-KRAS*^{G12V} classification system 332 333 for nearly 2% of PDAC patients with better survival. Also, we anticipate that these 334 patients may benefit from immunotherapy based on the results observed in xenograft 335 models, with the *HLA-A*02:01* showing a better response to immunotherapy due to its ability to bind *KRAS*^{G12V} neoantigens (31). In contrast, approximately 40% of PDAC 336 patients with KRAS^{G12D} mutated tumors demonstrated the poorest survival outcomes 337 338 in TCGA, independent of their HLA allele. This significantly narrows the therapeutic 339 options for these patients, potentially restricting them to systemic chemotherapy alone. 340 Given that KRAS mutations are neoantigens capable of binding the HLA-341 A*02:01 protein and initiating an immune response, we hypothesize that HLA-A*02:01-KRAS^{G12V} individuals might have an enhanced immune response 342 343 characterized by increased infiltration of anti-tumor immune cells, particularly CD8⁺ 344 T cells, compared to those with the allele and another KRAS mutation. Conversely, 345 patients with KRAS^{G12D} mutated tumors might either produce less immunogenic 346 neoantigens or exhibit a higher infiltration of cells able to promote tumor tolerance. 347 This results in a reduced ability of cytotoxic T cells to recognize and target the tumor cells. Interestingly, we discovered that KRAS^{G12D} PDAC tumors exhibited higher 348 349 expression levels of IFN- γ in comparison to other *KRAS* mutated tumors. The

differences in survival that we found in KRAS^{G12D} PDAC tumors might be due to 350 351 elevated IFN- γ levels upregulate PD-L1 expression, which binds to PD-1 receptors on 352 T cells, inhibiting their activity and the recruitment of regulatory T cells (Tregs) and 353 myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment (37). In 354 addition, high IFN PDAC tumors have been associated with worse overall survival, 355 due to a higher activation of stroma contributing to tumor growth (38). Altogether might explain the differences in survival that we found in *KRAS*^{G12D} PDAC tumors. 356 Consistently, a recent study published by Till et al., 2024, demonstrated that the 357 clearance of ct*KRAS*^{G12D} is associated with improved overall outcomes in metastatic 358 359 PDAC. This might be due to the immune system no longer recognizing the G12D 360 neoantigen, leading to reduced IFN- γ levels (39).

361 Beyond A*02:01, we identified three additional alleles associated with PDAC 362 risk in our meta-analysis. Among them, HLA-DPB1*04 was associated with an 363 increased risk of PDAC, with haplotypes containing this allele also showing an 364 increased risk. Limited information is available on the role of this allele in cancer (40). 365 Previous studies have shown that the risk allele *HLA-B*39* is associated with Grave's 366 disease (41) while the protective allele HLA-B*49 has been inversely associated with 367 COVID-19 (42). Nevertheless, our study is the first to report an association between 368 these alleles and cancer risk. Finally, HLA-A*26:01 was associated with an increased 369 risk of PDAC and inversely associated with nasal allergies and asthma in the 370 PanGenEU population. These results point to a possible explanation of previous 371 findings showing an inverse association between atopic comorbidities and PDAC risk 372 (10). While the meta-analysis combining PanGenEU and UKB data threw a risk 373 estimate (OR=1.07), it lacked statistical significance. This could be accounted for by 374 the low AF of *HLA-A**26:01 in UKB population (0.02) vs the AF in PanGenEU

375 (0.06), the latter AF being similar in most European countries with UK differing in the 376 AF by >50%. *HLA-A*26:01* has been reported to be associated with an increased risk 377 of non-Hodgkin lymphoma (OR=8.5, p-value= 2.6×10^{-2}) (43). Importantly, including 378 these alleles in a non-genetic-based cumulative risk score significantly altered the risk 379 of developing PDAC, either increasing or decreasing it substantially.

380 Our study has some limitations. First, the analyses employed self-reported 381 epidemiological information from subjects included in the studies that could lead to 382 misclassification of the risk factors and comorbidities, such as asthma and rhinitis. 383 However, our meta-analysis using the estimates of both PanGenEU and UKB 384 populations allowed us to minimize this potential bias. In addition, we restricted the 385 analyses to the Caucasian population; therefore, the impact of *HLA* alleles on PDAC 386 risk and prognosis in other ethnic groups should be further assessed. Additionally, the 387 MHC region is one of the most polymorphic areas of the human genome, making it 388 challenging for association analyses to detect rare alleles that may play a crucial role 389 in PDAC risk.

390 Despite the above-mentioned limitations, our work has several strengths. We 391 performed an in-depth analysis of the relationship between the HLA region and PDAC 392 risk by employing state-of-the-art methodology using important resources from two 393 large and independent study populations with complementary designs: case-control 394 and cohort. We corrected for population stratification by adjusting for the PCAs. 395 Additionally, the association with PDAC prognosis was first conducted with 396 PanGenEU study and further validated with data from three additional independent 397 datasets: UKB, TCGA, PAN-NGS, and Caris.

Our findings provide a strong basis for *HLA-A*02:01*, a single biomarker to be considered in improving PDAC prevention and risk stratification, allowing for

16

400	identifying patients who may require more aggressive monitoring or treatment due to
401	their lower genetic risk of mortality. These latter results warrant improving clinical
402	trials based on HLA allele and KRAS mutation profiling. Future studies should also
403	include PDAC subtypes in the association analysis and extend the scope to other
404	KRAS-related cancer types. Since tumors can lose the expression of the HLA alleles,
405	we suggest assessing whether this loss is happening in specific alleles with a
406	protective role. Finnaly, given the crucial role of HLA alleles in immune responses, we
407	suggest evaluating the immunotherapy response in PDAC patients according to their
408	HLA allelic profile.

409

410 MATERIAL AND METHODS

411 *Ethics Statement*

IRB ethical approval and written informed consent were obtained by all participating
centers contributing to PanGenEU, and study participants, respectively. The study was
conducted in accordance with the Helsinki Declaration.

415

416 *Study populations*

In this study, we employed the resources of the PanGenEU case-control study, the
UKB cohort, and datasets from The Cancer Genome Atlas (TCGA), PAN-NGS trial
from Erasmus Medical Center (EMC), Rotterdam, and Caris trial from Vall d'Hebron
University Hospital (VHIO), Barcelona.

421 PanGenEU study details have been reported elsewhere (9-11,44). It is a 422 multicentric case-control study on PDAC conducted in 28 centers across Spain, Italy, 423 Sweden, Germany, the UK, and Ireland from 2009-2014 and 2016-2018. Newly 424 diagnosed PDAC patients over 18 years of age were recruited. Eligible controls were 425 hospital inpatients with primary diagnoses not associated with any of the well-known 426 PDAC risk factors. Controls for Ireland and Sweden were population-based. 427 Epidemiological information was collected through direct in-person interviews by 428 trained health monitors using structured questionnaires, including information about 429 lifestyle, environmental exposures, and medical history (9). The individuals were 430 genotyped with the Infinium OncoArray-500K (45) and missing genotypes were 431 imputed using IMPUTE2 v2 (46) and 1000Genomes (Phase 3, v1) as reference (47). 432 Quality control filters included the missing call rate, unexpected heterozygosity, 433 discordance between reported and genotyped gender, unexpected relatedness, and 434 estimated European ancestry < 80%. Once those samples were filtered out, genotyped data from 1,317 cases and 700 controls were employed for *HLA* allele imputation andassociation analyses.

437 UKB is a prospective cohort study of approximately 500,000 individuals from 438 the United Kingdom (48). The UKB Axiom array was used for genotyping 450,000 439 subjects, and the remaining 50,000 individuals were genotyped with the UK BiLEVE 440 Axiom array. Based on their primary International Classification of Diseases (ICD9 441 and ICD10) codes, we selected 935 PDAC patients (Supplementary Table S8). We 442 discarded the self-reported cases (N=45) to ensure PDAC diagnosis reliability and 443 those individuals with no Caucasian genetic ethnicity (N=129), resulting in a final set 444 of 761 PDAC cases. After selecting Caucasian individuals without a history of cancer 445 and with the same ICD9 and ICD10 codes as PanGenEU controls (10), the final 446 dataset of controls included 95,050 subjects.

447 TCGA, established in 2006 by the National Cancer Institute and the National 448 Human Genome Research Institute, is one of the largest databases of cancer genomics 449 data (49). TCGA has genetic information for 33 cancer types, genotyped with the 450 Affymetrix 6.0 SNP array. We collected information on outcome, HLA alleles typed 451 with the Optitype tool (50), and KRAS mutations from PDAC, colorectal, stomach 452 adenocarcinoma, and Non-Small Cell Lung Cancer (NSCLC) patients. We kept for the 453 analysis Caucasian individuals and those patients with complete data, 101 PDAC, 185 454 colorectal, 196 stomach adenocarcinoma, and 620 NSCLC. Additionally, we 455 employed data from Thorsson et al, 2018 to assess the immune landscape of the 101 TCGA PDAC tumors. 456

The PAN-NGS trial (CCMO ID NL75415.078.20) includes PDAC patients from twelve centers throughout the Netherlands who were prospectively recruited from April 2021 to June 2023. Local review committees approved the trial. Eligible

19

460 patients had cytologically or histologically confirmed PDAC, were aged 18-60 years 461 at diagnosis, had an Eastern Cooperative Oncology Group performance score of 0-2, 462 and had an estimated life expectancy of at least twelve weeks. Patients were excluded 463 when they did not want to know if alterations might be associated with genetic predisposition of cancer or in case of locally advanced or local recurrence of PDAC 464 465 without histological tissue readily available. Clinical data were collected at 466 participating centers and supplemented as needed. Clinical information was obtained 467 at the site of the participating centers, and missing information was requested if were 468 also treated in other hospitals. A final dataset of 108 PDAC patients was employed for 469 the subsequent analysis.

470 *Caris clinical trial* is a retrospective single-center dataset involving patients 471 with PDAC treated at Vall d'Hebron University Hospital between 2021 and 2023. 472 Eligible participants were over 18 years old, had histologically confirmed PDAC, and 473 underwent molecular analysis with the Caris Life Sciences sequencing panel. 474 Exclusion criteria were non-adenocarcinoma pancreatic tumors, poor-quality samples 475 unsuitable for sequencing, inadequate follow-up, or lack of written informed consent. 476 Clinical data were collected at diagnosis, and a multidisciplinary team assessed the 477 clinical stage. The Ethics Committee of the Vall d'Hebron University Hospital 478 (PR(AG)651/2023) approved the study. Complete data was obtained for 145 PDAC 479 patients and included in the analysis.

480

481 HLA (or MHC) alleles assessment

HLA class I and II alleles were first imputed using genotyped data from the
PanGenEU study. We took advantage of the imputed *HLA* alleles from UKB, TCGA,
Erasmus MC, and Caris subjects.

485	PanGenEU study: The imputation was done by SNP2HLA software (version v
486	1.0.3) (51) considering 5,790 SNPs within the MHC region with an info parameter
487	\geq 0.9. This info parameter ranges from 0 to 1 and assesses the quality/reliability for a
488	particular variant imputed through IMPUTE2. We focused on SNPs overlapping with
489	those from the Type 1 Diabetes Genetic Consortium (T1DGC) V1.0.3, the largest
490	European reference panel (52). This dataset includes 5,225 individuals with
491	genotyping data for 7,238 SNPs, 424 HLA alleles (126 1-field and 298 2-field alleles),
492	and 1,276 HLA amino acids. It allowed an accurate imputation of classical HLA
493	alleles and amino acids of class I (HLA-A, -B, and -C) and class II (HLA-DPB1, -
494	DPA1, -DQB1, -DQA1, and -DRB1) genes. We excluded HLA alleles that were not in
495	Hardy-Weinberg equilibrium (HWE) in controls (p-value<10 ⁻⁶), calculated using the
496	HardyWeinberg R package V1.6.3 (53), those with a bad imputation quality
497	(info<0.3), as well as those with an allele frequency (AF) <5%, ending up with 40
498	alleles of 1-field, and 39 alleles of 2-fields.

UKB information on 362 *HLA* alleles across eleven loci (*HLA-A*, -*B*, -*C*, -*DPB1*, -*DPA1*, -*DQB1*, -*DQA1*, -*DRB1*, -*DRB2*, -*DRB3*, -*DRB4*, and -*DRB5*) was
available and obtained through the HLA*IMP:02 program (54).

502 *TCGA*: *HLA* class I alleles from the colorectal, stomach, and NSCLC tumors 503 were inferred from normal WES using polysolver (55). Then, xHLA (56) was 504 employed to infer the *HLA* I and *HLA* II alleles (*HLA-A*, *-B*, *-C*, *-DPB1*, *-DQB1*, and *-*505 *DRB1*) from normal WES of the PDAC patients.

506 *Erasmus MC*: *HLA* genotype results were determined based on information 507 from mRNA isolated from a formalin-fixed paraffin-embedded tumor sample using 508 the Agilent SureSelectXT Low Input Library prep chemistry, optimized for FFPE

tissue, in conjunction with the SureSelect Human All Exon V7 bait panel (48.2 Mb)

510 and the Illumina NovaSeq.

511 Caris clinical trial: HLA genotypes were obtained from Caris Life Sciences 512 reports for all patients. Genomic DNA was isolated from microdissected, formalin-513 fixed paraffin-embedded tumor samples and analyzed using the Illumina NovaSeq 514 6000 sequencers. A hybrid pull-down panel of baits designed to enrich for more than 515 700 clinically relevant genes at high coverage and high read-depth was used, along 516 with another panel designed to enrich for additional >20,000 genes at a lower depth. 517 To assist with gene amplification/deletion measurements and other analyses, a 500Mb 518 SNP backbone panel (Agilent Technologies) was included. Analytical validation for 519 *HLA* genotyping showed >99% concordance with a validated comparator method.

520

521 HLA haplotype assessment

522 We inferred the haplotypes independently in each population using the *haplo.stats* R 523 package (57) after phasing with BEAGLE (58) and considering the HLA gene 524 combinations prevalent in the Net Allele Database (28). A final set of 3,129 525 haplotypes were inferred in the PanGenEU individuals using 262 1-field HLA alleles 526 across all eight loci with an info parameter reflecting imputation quality >0.3. In the 527 UKB study, a final set of 148 and 57 1-field HLA class I and HLA class II haplotypes, 528 respectively, were identified using 141 1-field HLA alleles. No HLA haplotype 529 assessment was done for the TCGA population.

530

531 *Statistical analyses*

We assessed the association between the *HLA* region and PDAC risk for the individual *HLA* alleles and haplotypes within each study population. Subsequently, we combined

the summary statistics using a meta-analysis approach. Then, we studied the association of the *HLA* alleles with well-established PDAC risk factors. Additionally, we investigated the heritability explained by *HLA* class I and class II alleles (**Fig. 1**). We did not consider further the analysis at the amino-acid level because significant results at the individual level were not found (**Supplementary Table S9**). Finally, prognostic analyses integrated *HLA* alleles and *KRAS* mutational profiles.

540

541 HLA allele-based association analysis with PDAC risk. Association analyses were 542 done using the *PLINK* V1.9 software (59). In the PanGenEU setting, we tested the 543 association between the HLA alleles and PDAC risk at the individual level by 544 estimating the Odds Ratios (OR) and 95% Confidence Intervals (CI) through logistic 545 regression models including age, gender, the European region, and the first five 546 principal components (PCAs) to correct for population stratification. We considered 547 the three Modes of Inheritance (MoI) for 424 PanGenEU HLA class I and II alleles 548 with AF > 0.05. In UKB, we included the I- and II-fields HLA alleles with an AF 549 >0.1% (60.61). We performed logistic regression models adjusting for the same 550 covariates as in the PanGenEU models, plus the type of genotyping array and center of 551 inclusion.

A posterior meta-analysis using a random-effects model was performed with the *rma.uni* function of the *metafor* R package (62), combining the risk estimates of *HLA* alleles for PDAC with a nominal p-value<0.1 from the association analysis in PanGenEU and UKB studies, followed by multiple testing correction.

556

HLA allele-based association analysis with established PDAC risk factors. We used
logistic regression models to assess the association between *HLA* alleles significantly

associated with PDAC risk in the previous meta-analyses with established PDAC risk factors such as Family History of Pancreatic Cancer (FHPC), T2DM, obesity, and tobacco and alcohol consumption, as well as with PDAC protective factors (asthma and nasal allergies). We restricted these analyses to the controls from each study. Then, we performed a meta-analysis by applying a random-effects model. A cumulative PDAC risk score for the most promising alleles was computed by using the estimates obtained in the meta-analysis including PanGenEU and UKB.

566

Haplotype association analysis. We used the *haplo.stats* R package (version 1.7.9) to perform the statistical association analysis of the PanGenEU and UKB *HLA* haplotypes with PDAC risk. We employed a logistic regression model adjusted for the same covariates as in the previous analyses. We considered the three MoIs in each study population. Multiple testing correction was applied for each gene combination separately after discarding the low prevalence *HLA* haplotypes (i.e., frequencies either <5% or <0.1% in PanGenEU and UKB, respectively).

574

575 Estimation of the heritability explained by HLA class I and class II alleles

We applied a Bayesian multi-kernel-based regression (63) to estimate the genetic variance explained by *HLA* class I and *HLA* class II alleles using the resources of the PanGenEU study:

$$y = X\beta + Zh_I + Zh_{II} + \varepsilon$$

where the response variable *y* is a vector of case/control outcomes, *X* is an incidence or design matrix relating the adjusting covariates to each individual, β is the corresponding regression coefficient, *Z* is a design matrix allocating records ((*y*) to the vector of *HLA* class I/II associated risk scores (h_l and h_{ll}), and ε is a vector of random

583 normal deviates with null mean and variance σ_{ε}^2 that includes model misspecification 584 and environmental effects not considered in this model. The two genetic and residual 585 variances were assumed to follow the distributions $h_l \sim N(0, H I \sigma_{HLA-I}^2)$, 586 $N(0, H_{II}\sigma_{HLA-II}^2)$ and $\varepsilon \sim N(0, I\sigma_{\varepsilon}^2)$, where H_I and H_{II} correspond to the HLA class I and HLA class II alleles-derived relationship matrices between individuals, σ_{HLA-I}^2 and 587 σ^2_{HLA-II} are the genetic variances explained by HLA class I and II alleles, I is an 588 identity matrix, and σ_{ε}^2 corresponds to the residual variance. The prior distribution for 589 590 the genetic and residual variances were inverted chi-square distributions.

 H_{I} and H_{II} similarity matrices were constructed using a Gaussian kernel with the *G.matrix* function of *snpReady* R package (64). Estimates of the unknown parameters were obtained from their posterior distributions using a Gibbs sampling implemented in the *BGLR* R package. We ran a McMC chain of 500,000 iterations, and the first 100,000 were discarded as burn-in.

596

597 HLA allele-based survival analysis with PDAC risk. We assessed patient survival 598 based on the presence or absence of the HLA alleles, with a strong prior on HLA-599 A*02:01. To this end, we used the survival data of 425 PDAC cases from PanGenEU, 600 506 from UKB, 101 from TCGA (98 when we account for the stage of the tumor), and 601 145 from the Caris clinical trial. First, we assessed the overlap of the HLA class I and 602 II alleles between the three study populations. We computed Hazard Ratios (HR) and 603 95%CI using Cox proportional-hazards regression models for each population 604 separately under (co-)dominance MoIs. Adjustment covariates in PanGenEU models 605 were sex, age at diagnosis, center, tumor stage, and the first PCAs; for UK Biobank, 606 we included sex, age at diagnosis, genotyping array type, recruitment center and the 607 first five PCAs; for the TCGA and Caris models, we considered sex, age at diagnosis,

and tumor stage. Finally, we meta-analyzed the results from the four populations using

- 609 the function *rma.uni* from the *metafor* R package.
- 610

611 Association analysis between HLA-A*02:01 and KRAS common mutations. Based on 612 previous reports pointing to a joint effect of HLA-A*02:01 and KRAS mutations 613 (31,36), we further explored the interaction between these biomarkers using TCGA 614 data. We first assessed the association between HLA-A*02:01 and well-established 615 KRAS missense mutations at codons 12 (G12A, G12C, G12D, G12F, G12R, G12S, 616 G12V), 13 (G13C, G13D), and 61 (O61H, O61K, O61L, O61R) using logistic 617 regression models in tumors with high proportion of KRAS mutations (PDAC, 618 colorectal, stomach, and NSCLC) (Supplementary Table S10). As the reference 619 category, we used the non-G12V mutations for PDAC and colorectal cancer and the 620 non-G12C for NSCLC. We initially assessed the association within each specific 621 cancer type individually. Subsequently, we pooled the data from all cancer types into a 622 single model, adjusting for cancer type. Finally, we used a Cox proportional-hazards 623 regression model to evaluate whether the interaction between HLA-A*02:01 and the specific KRAS^{G12V} and KRAS^{G12D} mutations was associated with overall survival in 624 625 PDAC. The same covariates mentioned in the previous paragraph and the Moffit 626 subtype of the tumor were employed to adjust these models. We used a Wilcoxon test 627 to evaluate whether the associations found in overall survival could be explained by 628 infiltrated immune components. Differences were considered significant at pvalue<0.05. 629

To validate the interaction between the HLA-A*02:01 and the *KRAS* mutations, we used data from two independent populations, the Erasmus MC study and the Caris clinical trial. We analyzed the interaction between the *HLA-A*02:01*

633	allele and the $KRAS^{G12V}$ mutation in each population, adjusting for variables such as
634	sex, age at diagnosis, tumor stage, and treatment for Caris, and the same variables plus
635	center of inclusion for Erasmus MC. We then conducted a meta-analysis using a
636	random-effects model. Finally, we examined the effect of the interaction within each
637	population by stratifying patients based on tumor stage (stages I-II and stages III-IV)
638	and conducted separate meta-analyses for these subgroups.
639	

Langtry et al_HLA_MS_23082024

640 **DECLARATIONS**

Availability of data and materials: The datasets generated and/or analyzed during
the current study are not publicly available due to the sensitive nature of genetic data
but are available from the corresponding author upon reasonable request.

644 **Competing interests:** The authors declare that they have no competing interests.

645 **Funding:** The work was partially supported by Pancreatic Cancer Collective (PCC): Lustgarten Foundation & Stand-Up to Cancer (SU2C #6179); Fondo de 646 647 Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain (#PI061614, 648 #PI11/01542, #PI0902102, #PI12/01635, #PI12/00815, #PI15/01573, #PI18/01347, 649 #PI21/00495); Red Temática de Investigación Cooperativa en Cáncer, Spain 650 (#RD12/0036/0034, #RD12/0036/0050, #RD12/0036/0073); EU-6FP Integrated 651 Project (#018771-MOLDIAG-PACA), EU-FP7-HEALTH (#259737-CANCERALIA, 652 #256974-EPC-TM-Net); Associazione Italiana Ricerca sul Cancro (IG 26343); 653 Fondazione Cariverona: Oncology Biobank Project "Antonio Schiavi" (prot. 203885/2017); Italian Ministry of Health through Fondazione Italiana Malattie 654 655 Pancreas (FIMP_CUP J37G22000230001); Cancer Focus Northern Ireland and 656 Department for Employment and Learning; and ALF (#SLL20130022), Sweden, 657 Cancer Research UK (C7690/A26881) and Pancreatic Cancer UK.

Authors' contributions: Study conception: NM, ELM. Design of the work: AL, RR,
ELM, NM. Data acquisition: RTL, AC, CvE, TM, MH, MI, XM, JML, CM, JP, MO,
VMB, AT, AF, LMB, TCJ, EFM, TG, WG, LS, IF, GS, LLC, JB, EC, LI, JK, BK,
JM, DO, AS, WY, JY, FXR, NM, and rest of the PanGenEU Investigators. Data
analysis: AL, LA, SS, ELM. Interpretation of data: AL, RR, FXR, ELM, NM.
Creation of new software used in the work: No one. Drafting the work or substantively

revising it: AL, RR, FXR, ELM, NM. Approval of the submitted version (and any substantially modified version that involves the author's contribution to the study): ALL AUTHORS. Agreement on both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved and the resolution documented in the literature: ALL AUTHORS.

671 Acknowledgements The authors thank the patients, coordinators, field and 672 administrative workers, and technicians of the European Study into Digestive Illnesses 673 and Genetics (PanGenEU) and TCGA studies. This research has been conducted using 674 the UK Biobank Resource under Application Number 47884. This research was 675 performed using resources generated by Type 1 Diabetes Genetics Consortium, a 676 collaborative clinical study sponsored by the National Institute of Diabetes and 677 Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious 678 Diseases (NIAID), National Human Genome Research Institute (NHGRI), National 679 Institute of Child Health and Human Development (NICHD), and Juvenile Diabetes 680 Research Foundation International (JDRF) and supplied by NIDDK Central 681 Repository (NIDDK-CR). This manuscript was not prepared under the auspices of the 682 T1DGC study and does not necessarily reflect the opinions or views of the T1DGC 683 study, study sponsors, NIDDK-CR, or NIH. The results here are in part based upon 684 data generated by the TCGA Research Network: https://www.cancer.gov/tcga.

685

686 **REFERENCES**

- Connor AA, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating
 omics and clinical data. Nat Rev Cancer. Nature Publishing Group; 2022;22:131–42.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for
 Clinicians. 2020;70:7–30.
- Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an
 overview. Nat Rev Gastroenterol Hepatol. Nature Publishing Group; 2009;6:699–708.
- 4. Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all
 cancers combined and survival adjusted for age and sex for each cancer in England and
 Wales, 1971-2011: a population-based study. Lancet. 2015;385:1206–18.
- 5. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of Cancer
 Incidence in the United States: Burdens Upon an Aging, Changing Nation. JCO. Wolters
 Kluwer; 2009;27:2758–65.
- 6. Singhi AD, Koay EJ, Chari ST, Maitra A. Early Detection of Pancreatic Cancer:
 700 Opportunities and Challenges. Gastroenterology. 2019;156:2024–40.
- 701 7. Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer clinical challenges and opportunities. Nat Rev Clin Oncol. Nature Publishing Group; 2020;17:527–40.
- Gobbi PG, Bergonzi M, Comelli M, Villano L, Pozzoli D, Vanoli A, et al. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer. Cancer Epidemiology. 2013;37:186–90.
- 9. Gomez-Rubio P, Zock J-P, Rava M, Marquez M, Sharp L, Hidalgo M, et al. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut. BMJ
 Publishing Group; 2017;66:314–22.
- Gomez-Rubio P, Piñero J, Molina-Montes E, Gutiérrez-Sacristán A, Marquez M, Rava
 M, et al. Pancreatic cancer and autoimmune diseases: An association sustained by
 computational and epidemiological case-control approaches. International Journal of
 Cancer. 2019;144:1540–9.
- 11. López de Maturana E, Rodríguez JA, Alonso L, Lao O, Molina-Montes E, MartínAntoniano IA, et al. A multilayered post-GWAS assessment on genetic susceptibility to
 pancreatic cancer. Genome Med. 2021;13:15.
- Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, et al. Association
 analysis identifies 65 new breast cancer risk loci. Nature. Nature Publishing Group;
 2017;551:92–4.
- Lan Q, Hsiung CA, Matsuo K, Hong Y-C, Seow A, Wang Z, et al. Genome-wide
 association analysis identifies new lung cancer susceptibility loci in never-smoking
 women in Asia. Nat Genet. Nature Publishing Group; 2012;44:1330–5.
- 14. Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, et al.
 Association of variations in HLA class II and other loci with susceptibility to EGFRmutated lung adenocarcinoma. Nat Commun. Nature Publishing Group; 2016;7:12451.

726 727 728 729	15.	Aterido A, Cañete JD, Tornero J, Ferrándiz C, Pinto JA, Gratacós J, et al. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. Annals of the Rheumatic Diseases. BMJ Publishing Group Ltd; 2019;78:355–64.
730 731 732 733	16.	Merkel PA, Xie G, Monach PA, Ji X, Ciavatta DJ, Byun J, et al. Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis. Arthritis & Rheumatology. 2017;69:1054–66.
734 735 736 737	17.	Mendoza-Ramírez P, López-Olaiz MA, Morales-Fernández AL, Flores-Echiveste MI, de Jesus Casillas-Navarro A, Pérez-Rodríguez MA, et al. Class I MHC Polymorphisms Associated with Type 2 Diabetes in the Mexican Population. Genes (Basel). 2022;13:772.
738 739 740	18.	Jacobi T, Massier L, Klöting N, Horn K, Schuch A, Ahnert P, et al. HLA Class II Allele Analyses Implicate Common Genetic Components in Type 1 and Non-Insulin-Treated Type 2 Diabetes. J Clin Endocrinol Metab. 2020;105:dgaa027.
741 742 743	19.	Purohit A, Purohit BM, Mani A, Bhambal A. Genetic Implications of HLA-DR and HLA-DQ Genotype on Tobacco Smoking and Oral Submucous Fibrosis. Oral Health Prev Dent. 2020;18:455–60.
744 745 746	20.	Movahedi M, Moin M, Gharagozlou M, Aghamohammadi A, Dianat S, Moradi B, et al. Association of HLA class II alleles with childhood asthma and Total IgE levels. Iran J Allergy Asthma Immunol. 2008;7:215–20.
747 748 749 750	21.	Ribeyre C, Carlini F, René C, Jordier F, Picard C, Chiaroni J, et al. HLA-G Haplotypes Are Differentially Associated with Asthmatic Features. Frontiers in Immunology [Internet]. 2018 [cited 2022 Sep 29];9. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2018.00278
751 752 753	22.	Waage J, Standl M, Curtin JA, Jessen LE, Thorsen J, Tian C, et al. Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis. Nat Genet. Nature Publishing Group; 2018;50:1072–80.
754 755 756	23.	Filip I, Wang A, Kravets O, Orenbuch R, Zhao J, Perea-Chamblee TE, et al. Pervasiveness of HLA allele-specific expression loss across tumor types. Genome Med. 2023;15:8.
757 758 759	24.	Marty R, Kaabinejadian S, Rossell D, Slifker MJ, van de Haar J, Engin HB, et al. MHC- I Genotype Restricts the Oncogenic Mutational Landscape. Cell. 2017;171:1272- 1283.e15.
760 761 762	25.	Kloetzel PM. Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat Immunol. Nature Publishing Group; 2004;5:661–9.
763 764	26.	Unanue ER. From antigen processing to peptide-MHC binding. Nat Immunol. Nature Publishing Group; 2006;7:1277–9.
765 766 767	27.	Stenzel A, Lu T, Koch WA, Hampe J, Guenther SM, De La Vega FM, et al. Patterns of linkage disequilibrium in the MHC region on human chromosome 6p. Hum Genet. 2004;114:377–85.

768 769 770 771	28.	Gonzalez-Galarza FF, McCabe A, Melo dos Santos EJ, Takeshita L, Ghattaoraya G, Jones AR, et al. Allele Frequency Net Database. In: Boegel S, editor. HLA Typing: Methods and Protocols [Internet]. New York, NY: Springer; 2018 [cited 2022 Sep 12]. page 49–62. Available from: https://doi.org/10.1007/978-1-4939-8546-3_4
772 773 774	29.	Talwar JV, Laub D, Pagadala MS, Castro A, Lewis M, Luebeck GE, et al. Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility. The American Journal of Human Genetics. Elsevier; 2023;110:1138–61.
775 776 777	30.	Dyckhoff G, Herold-Mende C, Scherer S, Plinkert PK, Warta R. Human Leucocyte Antigens as Prognostic Markers in Head and Neck Squamous Cell Carcinoma. Cancers. Multidisciplinary Digital Publishing Institute; 2022;14:3828.
778 779 780 781 782	31.	Rive CM, Yung E, Hughes CS, Brown SD, Sharma G, Dreolini L, et al. Recombinant T cell receptors specific for HLA-A*02:01-restricted neoepitopes containing KRAS codon 12 hotspot mutations [Internet]. bioRxiv; 2020 [cited 2022 Sep 13]. page 2020.06.15.149021. Available from: https://www.biorxiv.org/content/10.1101/2020.06.15.149021v1
783 784 785	32.	Shenzhen BinDeBio Ltd. EGFRvIII/DR5/NY-ESO-1/Mesothelin CAR-T/TCR-T Cells Immunotherapy for Solid Malignancies [Internet]. clinicaltrials.gov; 2021 Feb. Report No.: NCT03941626. Available from: https://clinicaltrials.gov/ct2/show/NCT03941626
786 787 788 789	33.	Yamamoto Y. Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "DSP- 7888" for Acute Myeloid Leukemia Patients. [Internet]. clinicaltrials.gov; 2021 Feb. Report No.: NCT04747002. Available from: https://clinicaltrials.gov/ct2/show/NCT04747002
790 791 792 793 794 795	34.	PDC*line Pharma SAS. An Open-label, Dose-escalation, Phase I/II Study to Assess the Safety, the Tolerability, the Immunogenicity and the Preliminary Clinical Activity of the Therapeutic Cancer Vaccine, PDC*lung01, Associated or Not With Anti-PD-1 Treatment in Patients With Non-small-cell Lung Cancer (NSCLC) [Internet]. clinicaltrials.gov; 2022 Jul. Report No.: NCT03970746. Available from: https://clinicaltrials.gov/ct2/show/NCT03970746
796 797 798 799 800 801	35.	Greenwich LifeSciences, Inc. A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM- CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) [Internet]. clinicaltrials.gov; 2022 Nov. Report No.: NCT05232916. Available from: https://clinicaltrials.gov/ct2/show/NCT05232916
802 803 804 805 806	36.	Mishto M, Mansurkhodzhaev A, Ying G, Bitra A, Cordfunke RA, Henze S, et al. An in silico—in vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients. Frontiers in Immunology [Internet]. 2019 [cited 2022 Sep 13];10. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02572
807 808	37.	Fenton SE, Saleiro D, Platanias LC. Type I and II Interferons in the Anti-Tumor Immune Response. Cancers (Basel). 2021;13:1037.
809 810 811	38.	Espinet E, Gu Z, Imbusch CD, Giese NA, Büscher M, Safavi M, et al. Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin. Cancer Discovery. 2021;11:638–59.

812 813 814	39.	Till JE, McDaniel L, Chang C, Long Q, Pfeiffer SM, Lyman JP, et al. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Nat Commun. Nature Publishing Group; 2024;15:5763.
815 816 817	40.	Rivera Pirela S, Echeverría M, Márquez G, Carrillo Z, Parra Y, Salcedo P, et al. HLA- DPA1*/DPB1* en asociación con leucemias linfoides agudas y leucemias mieloides crónicas en mestizos venezolanos. Inmunología. 2014;33:81–6.
818 819 820	41.	Zawadzka-Starczewska K, Tymoniuk B, Stasiak B, Lewiński A, Stasiak M. Actual Associations between HLA Haplotype and Graves' Disease Development. J Clin Med. 2022;11:2492.
821 822	42.	Deng H, Yan X, Yuan L. Human genetic basis of coronavirus disease 2019. Signal Transduct Target Ther. 2021;6:344.
823 824 825	43.	Sayad A, Akbari MT, Mehdizadeh M, Taheri M, Hajifathali A. HLA-A*26 and susceptility of iranian patients with non-Hodgkin lymphoma. Iran J Immunol. 2014;11:269–74.
826 827 828 829	44.	Molina-Montes E, Gomez-Rubio P, Márquez M, Rava M, Löhr M, Michalski CW, et al. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. International Journal of Epidemiology. 2018;47:473–83.
830 831 832	45.	Amos CI, Dennis J, Wang Z, Byun J, Schumacher FR, Gayther SA, et al. The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev. 2017;26:126–35.
833 834 835	46.	Howie BN, Donnelly P, Marchini J. A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies. PLOS Genetics. Public Library of Science; 2009;5:e1000529.
836 837 838	47.	Durbin RM, Altshuler D, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A, et al. A map of human genome variation from population-scale sequencing. Nature. Nature Publishing Group; 2010;467:1061–73.
839 840 841	48.	Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.
842 843	49.	Weinstein JN, Collisson EA, Mills GB, Shaw KM, Ozenberger BA, Ellrott K, et al. The Cancer Genome Atlas Pan-Cancer Analysis Project. Nat Genet. 2013;45:1113–20.
844 845 846	50.	Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014;30:3310–6.
847 848 849	51.	Jia X, Han B, Onengut-Gumuscu S, Chen W-M, Concannon PJ, Rich SS, et al. Imputing Amino Acid Polymorphisms in Human Leukocyte Antigens. PLOS ONE. Public Library of Science; 2013;8:e64683.
850 851 852	52.	Rich SS, Concannon P, Erlich H, Julier C, Morahan G, Nerup J, et al. The Type 1 Diabetes Genetics Consortium. Annals of the New York Academy of Sciences. 2006;1079:1–8.

853 854	53.	Graffelman J. Exploring Diallelic Genetic Markers: The HardyWeinberg Package. Journal of Statistical Software. 2015;64:1–23.
855 856	54.	Dilthey A, Leslie S, Moutsianas L, Shen J, Cox C, Nelson MR, et al. Multi-population classical HLA type imputation. PLoS Comput Biol. 2013;9:e1002877.
857 858 859	55.	Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. Nature Publishing Group; 2015;33:1152–8.
860 861 862 863	56.	Xie C, Yeo ZX, Wong M, Piper J, Long T, Kirkness EF, et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2017;114:8059–64.
864 865 866	57.	JP S, DJ S. haplo.stats: Statistical Analysis of Haplotypes with Traits and Covariates when Linkage Phase is Ambiguous [Internet]. 2022 [cited 2022 Sep 12]. Available from: https://CRAN.R-project.org/package=haplo.stats
867 868	58.	Browning BL, Tian X, Zhou Y, Browning SR. Fast two-stage phasing of large-scale sequence data. The American Journal of Human Genetics. 2021;108:1880–90.
869 870 871	59.	Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.
872 873 874 875 876	60.	Venkataraman GR, Olivieri JE, DeBoever C, Tanigawa Y, Justesen JM, Dilthey A, et al. Pervasive additive and non-additive effects within the HLA region contribute to disease risk in the UK Biobank [Internet]. bioRxiv; 2020 [cited 2022 Sep 12]. page 2020.05.28.119669. Available from: https://www.biorxiv.org/content/10.1101/2020.05.28.119669v2
877 878 879	61.	Krebs K, Bovijn J, Zheng N, Lepamets M, Censin JC, Jürgenson T, et al. Genome-wide Study Identifies Association between HLA-B*55:01 and Self-Reported Penicillin Allergy. Am J Hum Genet. 2020;107:612–21.
880 881	62.	Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. Journal of Statistical Software. 2010;36:1–48.
882 883	63.	Wahba G. Spline models for observational data. Philadelphia, Pa: Society for Industrial and Applied Mathematics; 1990.
884 885 886	64.	Granato I, Fritsche-Neto R. snpReady: Preparing Genotypic Datasets in Order to Run Genomic Analysis [Internet]. 2018 [cited 2022 Sep 12]. Available from: https://CRAN.R-project.org/package=snpReady
887		

Table 1. Cumulative PDAC risk estimates (OR: odds ratio and CI: confidence interval) in the extreme scenarios according to the presence/absence of known risk factors (Type II diabetes, smoking, and family history of pancreatic cancer, FHPC) or protective factors (asthma and nasal allergies) in addition to the significant *HLA*

alleles identified in the meta-analysis.

	OR	L. CI	U. CI	p-value
High-risk scenario ^a	2.80	1.24	6.35	
High-risk scenario + HLA-B*39				1.17 x 10 ⁻¹
1 allele	3.85	1.20	12.32	
2 alleles	5.28	1.65	16.92	
High-risk scenario + HLA-DPB1*04				1.33 x 10 ⁻¹
1 allele	3.06	1.22	7.67	
2 alleles	3.34	1.33	8.37	
Low-risk scenario ^b	0.38	0.13	1.09	
Low-risk scenario + HLA-A*02:01				1.18 x 10 ⁻²
1 allele	0.32	0.1	1.03	
2 alleles	0.27	0.08	0.88	
Low-risk scenario + HLA-B*49				2.4 x 10 ⁻²
1 allele	0.19	0.03	1.07	
2 alleles	0.1	0.02	0.55	

Scenario a: smokers, diabetics or individuals with family history of cancer who did not have asthma nor allergies in the metaanalysis of the PangenEU and UK Biobank population.

Scenario b: asthmatic or allergic individuals who did not smoke, did not have diabetes, nor family history of cancer.

898 MAIN FIGURE LEGENDS

Figure 1. Study Flowchart: Overview of the complementary approaches adopted in this study to explore the role of *MHC* region in the PDAC susceptibility and prognosis.

Figure 2. Odds ratio (OR) and 95% confidence interval (CI) of the association
analyses between PDAC susceptibility alleles, as well as the allele frequency (AF): *HLA-A*02:01* (Figure 2A), *HLA-B*49* (Figure 2B), *HLA-B*39* (Figure 2C), and *HLA-DPB1*04* (Figure 2D) obtained in the meta-analysis and known risk/protective factors
for PDAC.

Figure 3. Hazard ratio (HR) and 95% confidence interval (CI) of the Cox proportional-hazards regression models under a dominance MoI obtained in the metaanalysis for the allele *HLA-A*02:01* when considering PanGenEU, UK Biobank, and TCGA (Figure 3A), and when including data from the Caris clinical trial in the metaanalysis (Figure 3B).

Figure 4. Kaplan-Meier curves of patients according to their KRAS mutational status
in *HLA-A*02:01* carriers with PDAC tumors harboring *KRAS*^{G12V} patients whose
tumors have other KRAS mutations who are carriers of *HLA-A*02:01* (Figures 4A
and Figure 4C) and non-carriers of that allele (Figures 4B and Figure 4D).

Figure 5. Kaplan-Meier curves of patients according to the presence or absence of the *HLA-A*02:01* allele in *KRAS*^{G12V} (Figures 5A) and *KRAS*^{G12V} (Figures 5B) mutated tumors.

Figure 6. Hazard ratio (HR) and 95% confidence interval (CI) of the Coxproportional-hazards regression models under a dominance MoI obtained in the meta-

- 921 analysis for the allele *HLA-A*02:01* for (A) stages I&II PDAC tumors from Erasmus
- 922 and TCGA study populations and (B) stages III&IV tumors from Erasmus MC and
- 923 Caris study populations.

924


925 Additional Files

- Annex 1. PanGenEU Investigators.
- **Table S1.**Baseline characteristics of the study populations.
- **Table S2**. Number of alleles of *HLA* Class I and Class II genes considered in the association analysis in each study population after filtering out the alleles with poor imputation quality.
- **Table S3**. *HLA* allele, 95% confidence intervals bounds (ci.lb and ci.ub), odds ratios (OR), p-value, and adjusted p-value and of the association meta-analysis between the *HLA* alleles and pancreatic ductal adenocarcinoma (PDAC) risk including the PanGenEU and UK Biobank study populations.
- **Table S4.***HLA* allele, frequency (Freq), Imputation quality (INFO), odds ratios
(OR), p-value, and adjusted p-value and of the association between the
HLA alleles and pancreatic ductal adenocarcinoma (PDAC) risk in the
PanGenEU study population.
- **Table S5.***HLA* allele, frequency (Freq), odds ratios (OR), p-value, and adjusted p-
value and of the association meta-analysis between the *HLA* alleles and
pancreatic ductal adenocarcinoma (PDAC) risk in the UK Biobank study
population.
- **Table S6.**Frequency in both populations (freq), Odd ratio (OR), confidence
interval (CI), and p-value (p) of the inferred haplotypes from *MHC* I and
II *HLA* genes significantly associated with PDAC risk by genome-wide
association studies considering an additive mode of inheritance.
- **Table S7.** Odd ratio (OR) and p-value (p) of the association between *HLA-A**02:01 and *KRAS* mutations across three different tumor types from TCGA data: PDAC, colorectal, and NSCLC (we excluded stomach because there was only one individual with G12V mutations).
- **Table S8.**ICD9 and ICD10 codes for PDAC in UK Biobank
- **Table S9.**Amino acid (AA), base pair (BP), Frequency (Freq), odds ratios (OR),
p-value, and adjusted p-value and of the association between the HLA
amino acids and pancreatic ductal adenocarcinoma (PDAC) risk in the
PanGenEU study populations.
- **Table S10.***KRAS* mutational status of PDAC, colorectal, stomach, and NSCLC
cancer types from the TGCA study.
- **Figure S1.** Whole landscape of the alleles of *HLA* class I and II genes at two-fields in PanGenEU (Figure S1A) and in UKBiobank (Figure S1B) study populations. The x-axis shows each of the imputed *HLA* alleles across the 8 studied loci. The y-axis, represents the frequency in the PanGenEU


and UK Biobank populations for each HLA allele.


- **Figure S2.** Scatter plots of the HLA allele frequencies in PanGenEU study population versus in T1DGC, which was used as a reference panel to impute the 1-field (Figure S2A) and 2- fields (Figure S2B) *HLA* alleles in PanGenEU.
- **Figure S3.** Scatter Plot of the allele frequencies in PanGenEU and UK Biobank populations, showing a moderate agreement.
- **Figure S4.** Odds ratio (OR) and 95% confidence interval (CI) of the association analyses between *HLA-A*26:01* and PDAC risk and PDAC risk/protective factors in PanGenEU population. FHPC: Family history of PC; BMI: body mass index.
- **Figure S5.** Venn diagram illustrating the overlap of *HLA* Class I and II gene alleles at two fields in the PanGenEU, UKBiobank, and TCGA study populations.
- **Figure S6.** Hazard ratio (HR) and 95% confidence interval (CI) of the Cox proportional-hazards regression models under a codominance MoI obtained in the meta-analysis for the allele *HLA-DPB1*04* when considering PanGenEU, UK Biobank, and TCGA.
- **Figure S7.** Hazard ratio (HR) and 95% confidence interval (CI) of the Cox proportional-hazards regression models obtained under the additive MoI in the meta-analysis of three populations for the 2-field alleles *HLA*-A*30:01 and *HLA-DPB1*09:01*.
- **Figure S8.** Boxplot showing the significant differences in IFN- γ levels between PDAC tumors with *KRAS*^{G12D} mutations vs any of the other KRAS mutated tumors obtained through the Wilcoxon test.
- **Figure S9.** Hazard ratio (HR) and 95% confidence interval (CI) of the Cox proportional-hazards regression models obtained under the additive MoI in the meta-analysis of three populations for the interaction between the HLA-A*02:01 allele with $KRAS^{G12V}$ mutations.

926



*Cases/controls








Figure 5




Figure 6

